Are We Poised for a Buying Spree?
With Current High Company Valuations M&As are Scarce
By Peter Winter
Mergers and acquisitions have always been a regular staple in the biotech industry . . . until this year that is. Can it be possible that there won't be at least one blockbuster deal executed by the end of December?